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Abstract 
The aim of this study was to identify barriers to effective breast, cervical and colorectal cancer 
screening programmes throughout the whole of the European region using the Barriers to Effective 
Screening Tool (BEST). The study was part of the scope of the EU-TOPIA (TOwards imProved 
screening for breast, cervical and colorectal cancer In All of Europe) project and respondents were 
European screening organisers, researchers and policymakers taking part in a workshop for the 
project in Budapest in September 2017. 67 respondents from 31 countries responded to the online 
survey. The study found that there are many barriers to effective screening throughout the system 
from identification of the eligible population to ensuring appropriate follow-up and treatment for 
the three cancers. The most common barriers were opportunistic screening, sub-optimal 
participation, limited capacity (including trained human resource), inadequate and/or disjointed 
information technology systems and complex administration procedures. Many of the barriers were 
reported consistently across different countries. This study identified the barriers that, in general, 
require further investment of resources. 
Introduction 
The European Union (EU) has issued recommendations for population-based breast, cervical and 
colorectal cancer screening programmes but a recent review of their performance found that most 
are not functioning optimally(International Agency for Research on Cancer, 2017). As part of the EU-
TOPIA (TOwards imProved screening for breast, cervical and colorectal cancer In All of Europe) 
project, we developed the Barriers to Effective Screening Tool (BEST). The instrument includes two 
sections evaluating the components of and barriers to an effective screening system. In each section, 
the format of the tool was based on a conceptual model that divided the cancer screening system 
into six sub-systems: knowledge generation, identification of the eligible population, maximising 
uptake (informed participation), successful operation of the programme, adequate follow-up and 
effective treatment for those who need it. A pilot exercise applied the instrument separately to 
breast, cervical and colorectal cancer screening programmes in the six core countries in the EU-
TOPIA project: Estonia, Finland, Hungary, Italy, the Netherlands and Slovenia. The results of this pilot 
are reported in the accompanying papers(Turnbull et al. 2018, and Turnbull et al. 2018) and the 
results of the pilot were used to compile a list of barriers to include in the tool. This paper aimed to 
apply the BEST instrument to additional countries throughout the European region to gain a wider 
view of the barriers to effective screening and validate the list of barriers from the pilot. 
Methods 
For this study we used an online version of the BEST instrument. A copy of the instrument is included 
in Appendix A. We updated the instrument following the pilot to include structured answers, based 
on the barriers highlighted in the pilots. This was to make the survey simpler to complete and 
analyse. However, we also allowed free text answers to enable us to capture any new barriers. 
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We circulated the instrument to all workshop participants prior to an EU-TOPIA meeting in Budapest 
in September 2017. Respondents accessed the survey via a link in the email that connected to an 
online portal where they could complete the survey and the authors could access the data. Most 
attendees were representatives from national or regional screening organisations, and researchers 
and policymakers from throughout the European region (including non-EU countries). All were 
experts in screening programmes for breast, cervical and/or colorectal cancer in their country.  
To avoid repetition, the instrument was applied once for all three cancer types. The pilot had shown 
many barriers to be similar across breast, cervical and colorectal programmes. At the end of the 
survey, we asked respondents to highlight any differences between cancer types. There was no time 
limit for completion although all surveys were completed within two weeks. Due to the diversity of 
the sample and practical difficulties for many respondents of meeting face-to-face, we did not 
require collated responses per country as we had done in the pilot. 
Results 
Sample characteristics 
The study included 67 respondents from 31 countries in the European region. The included countries 
were as follows (including the number of responses, if more than one): Albania, Austria, Belgium (3), 
Croatia (4), Cyprus, Czech Republic (3), Denmark (3), Estonia, Finland (2), France (5), Georgia, 
Germany, Hungary, Iceland, Ireland (2), Italy (2), Latvia (3), Luxembourg, Malta, Montenegro (2), 
Netherlands (4), Norway (2), Poland (2), Portugal, Romania, Serbia, Slovenia (6), Spain (4), Sweden 
(3), United Kingdom (3) and Switzerland. The response rate was 81% from 83 attendees, excluding 
individual members of the EU-TOPIA consortium who were also in attendance. The primary analysis 
included all barriers mentioned by any respondent in each country and results presented first 
exclude duplicate answers from the same country. The results by number of respondents are also 
included for information. 
Of the roles specified in the tool, the largest group of respondents included representatives from 
national screening organisation (n=29). The next largest group was researchers (n=12) followed by 
policymakers (n=9). Representatives from regional screening organisations (n=6) were the largest 
group of ‘others’. ‘Other’ roles (n=11) specified by respondents included researcher AND policy 
maker combined, national screening evaluation (3), cancer registry, epidemiologist, coordinator in 
the national public health institute, program coordinator, representative from the Ministry of 
Health, quality assurance and commissioner, and obstetrician/gynaecologist. 
 
Components of the screening programmes 
In the first section of the survey, we collected information on the components of the screening 
systems in each country. The description of the components of the screening systems included in 
this study were generally in line with those previously reported from the pilot in the accompanying 
papers(Turnbull et al. 2018 and Turnbull et al. 2018) and other reports describing the status of 
screening systems in Europe(International Agency for Research on Cancer, 2017). In brief, national 
health authorities (or ministries of health) and, to a lesser extent, national screening organisations or 
regional/municipal health authorities are responsible for assessing cancer screening needs, 
evaluating evidence and system design. This is also the case for protocol and process design, based 
primarily on European guidelines for cancer screening. Sources to identify the eligible population 
include population registers, health insurance registers or primary care registers. In most countries, 
programmes send a letter to invite eligible people for screening and appointments can be pre-
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allocated, with an option to change or made using the contact details provided or according to other 
local arrangements. Participation is most commonly monitored at a national level by the national 
health authority or screening organisation unless the programmes operate at a regional level. How 
quality is assessed varies by country. The responsibility for adequate follow-up and effective 
treatment for those that need it is split between national, regional and local organisations, and 
individuals. 
Number of barriers reported per respondent  
The average numbers of barriers reported per respondent for each of the sub-systems were: 
knowledge generation (2.4), identification of the eligible population (1.9), maximising uptake 
(informed participation) (3.4), successful operation of the programme (4.6), adequate follow-up (2.5) 
and effective treatment for those that need it (2.0). This totalled an average of 16.9 barriers 
reported per respondent, without rounding, for the breast, cervical and colorectal cancer screening 
systems overall. On average, respondents from a national screening organisation reported 18 
barriers, respondents from regional organisations reported 13.5 barriers, policy-makers reported 
16.6 barriers and researchers reported 14.3 barriers in total.  
Reported barriers to effective screening 
We identified the barriers to effective screening for each of the components of a cancer screening 
system: a.) knowledge generation, b.) identification of the eligible population, c.) maximising uptake 
(informed participation), d.) successful operation of the programme, e.) adequate follow-up, and f.) 
effective treatment for those that need it. Descriptions of each of these section headings are 
included in the survey in Appendix A. Given the small numbers of respondents per country, we 
conducted subgroup analyses by European region (North, East, South and West).  Figure 1 shows the 
average number of barriers reported by region, Figure 2 shows the ten most commonly reported 
barriers from the BEST tool and Table 1 shows the percentage of countries overall and in each region 
reporting each barrier by sub-system.  The results for each sub-system are discussed further below.  
Further subgroup analyses by survival for breast, cervical and colon cancer reported in the 
CONCORD-3 study for each country(Allemani et al., 2018) are included as supplementary material 
(Supplementary Figures S1-S6). 
Figure 1, Figure 2 and Table 1 about here 
a.) Knowledge generation 
The three most common barriers to knowledge generation, each reported in over half of countries, 
were insufficient numbers of trained professionals with knowledge of screening programmes, 
complex administrative procedures delaying protocol amendments, and insufficient monitoring of 
screening programmes (uptake, acceptability and outcomes). In the North and South, insufficient 
trained professionals and inadequate governance structures were particular issues whereas in the 
West, complex administrative procedures, insufficient monitoring and delays updating guidance 
were commonly reported. 
b.) Identifying the eligible population  
Overall, the three most commonly selected barriers to identifying those to be screened were the 
population register is not updated with changes of address, some eligible patients are excluded, and 
there is no follow-up of non-responders after initial screening invitations. The South and East, in 
particular, reported issues with the correctness and completeness of the population registers and 
the East and West frequently reported issues relating to eligible patients not being in the register or 
follow-up of non-responders.  
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c.) Maximising uptake (informed participation)  
In the vast majority of countries an important barrier to uptake is the existence of opportunistic 
screening occurring outside of the routine programme. The other three most common barriers, also 
in over half of countries, are that some people have beliefs and values that lead to non-participation, 
some people experience practical issues that lead to non-participation, and primary care physicians 
are not sharing information or promoting screening. Failure by primary care staff to promote 
screening and non-participation were a particular issue reported commonly in the West whereas 
opportunistic screening was a frequent issue in the South, and to a lesser extent in the West.  The 
North, South and East all highlighted issues relating to the monitoring of screening. 
d.) Successful operation of the programme 
The topmost barriers to operation from those reported, each in over two thirds of countries, are 
inadequate and/or disjointed information technology (IT) systems, data from opportunistic 
screening not being collected or shared, opportunistic testing failing to adhere to the same 
evidence-based screening policy, and limited capacity of screening programmes (insufficient human, 
physical and financial resources).  The East generally reported many operational issues relating 
opportunistic screening, scarce resources, problems establishing protocols and inadequate IT 
systems. The South also commonly reported opportunistic screening, logistical and monitoring issues 
whereas the North were mainly concerned with IT systems. Countries in the West were concerned 
by provider adherence and opportunistic screening, which may have related to private ownership.    
e.) Adequate follow-up  
The barriers to follow up are much more diverse, but insufficient monitoring and evaluation of non-
responders, lack of an organisation to monitor follow-up, and difficulties sharing data between 
clinics regionally and nationally are the most common.  Many in the East reported barriers 
throughout all aspects of this sub-system and in the West many reported issues with organisation, 
data sharing, provider adherence to recommendations, evaluation and addressing obstacles to 
participation. 
f.) Effective treatment for those that need it 
The three most frequently mentioned barriers to treatment, from all reported, were a lack of 
systematic monitoring or evaluation of treatment outcomes, failing to track information along the 
patient journey, and difficulties sharing and accessing data across different regions. The East and 
West, in particular, highlight issues with monitoring, tracking information and sharing data, as well 
as non-treatment due a variety of personal and practical issues. 
Other new barriers identified 
The survey allowed respondents to describe additional barriers not previously identified by the pilot, 
although the vast majority had already been identified. However, a few new ones were mentioned 
and applied across sub-systems: the need for comprehensive IT systems or equipment; insufficient 
capacity to ensure adequate coverage and minimise waiting times; and the requirement for 
additional payments by patients in some countries. For the generation of knowledge and 
effectiveness, slow and inadequate change to guidelines was also reported, albeit for different 
reasons among countries, including: competition from other or changing political priorities, divisions 
of responsibility between national and regional organisations, general health system change from 
public to private sector and reluctance to change traditional practice. Had these barriers been 
included as a choice response, more countries may have reported these barriers. 
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Differences between breast, cervical and colorectal programmes 
In certain countries, not all of the three cancer programmes are fully implemented at a population 
level. In Denmark, colorectal screening has only recently been rolled out, breast screening is new in 
Slovenia, and in Spain European guidance on population-based screening is not implemented for 
cervical cancer screening (screening being opportunistic). Germany and Sweden also note that not 
all programmes are running, Sweden only having mammography, and in Poland breast and cervical 
screening programmes have recently been stopped. Even in those countries where programmes are 
implemented, there is still need for a legislative basis for some programmes (Slovenia for breast and 
cervical screening), larger supported implementation (Albania for cervical cancer), or development 
of protocols (Hungary for cervical screening).  
Opportunistic screening is noted as an issue for cervical cancer screening (Belgium, Croatia, Hungary, 
Netherlands, Poland, and Spain) and breast cancer screening (France, Hungary, Luxembourg, and 
Netherlands). Participation seems a particular issue for colorectal cancer screening (Croatia, France, 
Italy, Malta, Poland, Spain). Low participation may be related to lack of awareness (Croatia, Italy, 
Malta) and populations including males being less likely to attend than exclusively female 
populations (Slovenia, Sweden). Different risk perceptions (Sweden, UK) and attitudes (Portugal) to 
different programmes are also reported. Different levels of participation across programmes are also 
noted in other countries (Latvia, Portugal and Slovenia) with particular mentions of Romania (low 
intensity and information for cervical) and Serbia (mammography having the highest attendance). 
Whilst not a system factor, information on barriers to participation is useful as it can inform system 
factors such as communication of information and appointment systems. 
Examples of differences between programmes relating to the different types of tests used were 
reported in response to this survey. As noted in Denmark, screening for each of the programmes is 
operated by different categories of health professionals. In Belgium, appointments must be made 
for mammography, in Norway cervical screening appointments have to be made with one’s own 
general practitioner or gynaecologist, whereas colorectal cancer screening with tests such as faecal 
immunochemical test (FIT) is self-sampling/by post (Belgium, Sweden).  
Resource allocation also differs between programmes according to survey respondents. In Italy it is 
noted that, whilst FIT has enabled the first stage to be operated at low cost, the bottleneck has 
moved to the second level, colonoscopy. Lack of colonoscopy capacity is also reported elsewhere 
(Netherlands, Romania, Spain, UK). In Portugal, access to colonoscopy screening is the major 
constraint, but Serbia reports availability of iFOB (immunochemical faecal occult blood) tests to be 
an issue. Shortages of mammography facilities (Serbia) and radiologists (Romania, UK) also highlight 
differences between programmes in different countries.  
Finally, monitoring of performance also varies between programmes and countries. Romania reports 
particular problems while, in the UK, IT issues have created difficulties.  
Overall findings 
While noting the considerable national variations reported above, it is also interesting to look at all 
responses, wherever they came from as results were generally similar with and without duplicate 
responses from the same country (Table 2).  
Table 2 about here 
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Discussion 
Summary of the evidence 
There was broad consistency across countries in terms of the most common barriers reported. 19 
barriers were each reported by over half of countries. The most common barrier was opportunistic 
screening outside of the population-based programme, not only being selected as a barrier to 
informed participation but also in terms of successful operation (data collection and sharing, 
adherence to evidence-based policy and increased cost). The vast majority of countries highlighted 
non-participation by individuals, mainly due to personal beliefs and values but also practical reasons. 
The most common barriers relating directly to health services organisation were limited capacity 
(human, physical and financial resource for successful operation as well as trained staff for 
knowledge generation), inadequate and/or disjointed IT systems and complex administration 
procedures delaying knowledge generation. All European regions reported barriers in all sub-
systems but patterns varied considerably in different parts of Europe. However, proportionally more 
countries in the East tended to highlight barriers to identifying eligible patients through accurate 
registers, following-up non-responders or those requiring more treatment, opportunistic screening, 
operational issues such as inadequate resources, organisation, protocols, and monitoring.  Countries 
in the North tended to highlight issues such as lack of trained professionals and weak governance, IT, 
and monitoring. The countries in the West were particularly concerned by administrative procedures 
delaying updates to guidance, non-participation, lack of follow-up of non-responders and non-
adherence to recommendations by providers.  In the South, opportunistic screening, problems 
identifying eligible patients, lack of trained staff, weak governance and logistics, and inadequate 
monitoring were frequently reported.  There were some differences between breast, cervical and 
colorectal programmes, mainly relating to stage of implementation, level of opportunistic screening 
and participation, type of test and resource allocation even though, on the whole, there were more 
similarities than differences.  
Strengths and limitations 
The sample covered 31 countries from the European region, thereby providing a wide perspective on 
current breast, cervical and colorectal cancer screening programmes in Europe. The sample included 
attendees at a workshop of the EU-TOPIA project who were experts in their national screening 
programmes. There was a high response rate; for all sub-systems, barrier data was provided for all 
countries in all but a very small number of cases (were individual respondents had not completed 
the form, other representatives from their country had largely provided data). The results of this 
study were generally consistent with the previous pilot study. No issues relating to the tool were 
reported and the structured answers added to the BEST tool after the pilot were appropriate.  
The selection of participants means that they likely had particular characteristics (e.g. being 
supportive of organised screening) that could bias the results compared with a broader sample, 
although it would then be necessary to recruit enough and to find ways to resolve disputes. The 
sample was not large enough to do sub-group analysis by role or country which would have required 
an identical quota of respondents by role for each country, hence we grouped countries by region 
and survival of those with the three cancers. Some countries had more respondents than others that 
may have influenced the overall results. A larger sample could also incorporate other stakeholders 
from the screening process including members of the screening population, local service providers 
and health professionals to widen the perspective further.  
Due to the time limitations in conducting the survey prior to the workshop, we did not apply a rating 
or ranking exercise to evaluate the importance of each barrier relative to the other reported 
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barriers. Moreover, we did not apply the CATWOE (Clients, Actors, Transformations, 
Weltanschauung, Owners, and Environmental) instrument as the pilot had indicated the need for 
specialists in health systems research to be involved in this analysis. Even though the structured 
nature of this version of the survey made the exercise quicker to complete and analyse, it may lead 
to some qualitative elements or subtle differences between countries being lost. This leaves a gap 
for future barrier research incorporating rating/ranking and the CATWOE approach, as well as 
further stakeholders. On average, more barriers were identified by respondents working at a 
national level compared with those working at a regional level. This may be because the national 
level organisations have more of an oversight of all the components of the system whereas regional 
organisations focus on certain aspects. 
Comparison with the literature 
This study, which uses a soft (health) systems approach and explores the views of expert 
representatives from screening organisations, researchers and policy-makers, gives a fresh 
perspective on barriers to organised cancer screening in Europe. Much of the existing literature has 
been focused on barriers to individual participation from the individual’s perspective. It did not 
identify any similar studies examining all three cancer screening programmes across Europe, 
including non-EU states.  
The piloting of the BEST instrument compared its results with the EU report(International Agency for 
Research on Cancer, 2017) on the status of all three cancer programmes. Whilst comprehensive in 
terms of data, this report is not focused on health service, particularly soft system, barriers. The 
EUROCHIP study(Drs Paolo Baili, 2012) went some way to evaluating barriers from a health systems 
perspective, focusing on cervical cancer screening in Eastern Europe(Anttila et al., 2010). This was 
added to by a survey of screening policies and coverage(Anttila et al., 2009, Nicula et al., 2009) 
(similar to the BEST tool evaluation of components of the system) and a process performance 
analysis(Ronco et al., 2009). In addition, other publications highlighted the lack of organised 
programmes in old member states(Arbyn et al., 2009). Evaluations have found that the performance 
of screening programmes and the barriers that give rise to inequalities are influenced by a complex 
system of factors(Dobrossy et al., 2014, Dobrossy et al., 2015). Despite the eight years that have 
since passed, many of the barriers highlighted in these older studies (e.g. non population-based 
screening, non-participation, inadequate legislation, disjointed information systems, and lack of 
resources) are still prevalent today, as highlighted by our study, in many countries across Europe.  
Altobelli and Lattanzi(Altobelli and Lattanzi, 2014) have noted the diversity in EU countries in terms 
of target population coverage and age and in the techniques deployed, but with all constrained by 
inadequate participation. More recent publications concur that breast cancer programmes are in 
place in most EU member states but there are still differences, and inadequacies, in terms of 
implementation and participation(Deandrea et al., 2016). Inequalities in participation in breast and 
cervical cancer screening programmes, based on socioeconomic status, have been shown to be 
higher in countries without population-based cancer screening programmes compared with 
countries with these programmes(Palencia et al., 2010). However, while much research on 
participation has concentrated on the characteristics of individuals invited for screening, such as age, 
education, and health status, these do not explain cross country differences in screening 
performance(Wubker, 2014). This highlights the importance of examining system-level 
characteristics. Moreover, where individual characteristics, such as socioeconomic position, do have 
an impact, it is greater with opportunistic than population-based programmes(Walsh et al., 2011). 
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There is a particular lack of data on health system barriers to effective colorectal cancer screening in 
Europe. This could be explained, in part by the use of self-sampling at home using FIT which 
eliminates the need to attend an appointment for an invasive test in the first instance (although 
colonoscopy is still used at a later stage). A key focus of the evidence is for participation and factors 
influencing this(Honein-AbouHaidar et al., 2016). According to West et al.(West et al., 2009), whilst 
there may be differences in approach to colorectal screening, there are similar barriers to overcome 
in Europe. 
Implications 
There is a paucity of data focusing on the health systems aspects of barriers to effective cancer 
screening programmes. This study goes some way to filling the gap in the evidence. This study 
provides useful insights to national and regional-level policy-makers so that they can better 
understand where investment is needed to develop more effective screening programmes. 
However, more research is still needed to understand the importance of each of the barriers and 
which should be prioritised in terms of investment of resources. Moreover, the views of local 
providers, health professionals and the eligible population from the general public should be 
consulted. 
Conclusion 
This study shows that, despite much progress in implementing population-based programmes, there 
are still considerable barriers to their effective operation, throughout the European region, 
indicating that, whilst investing resource in some areas for improvement is important, this needs to 
go hand in hand with an in-depth soft-system analysis of the screening system, identifying barriers to 
be overcome.  
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Cancer screening systems survey 
We are writing to seek your assistance with an analysis of the systems for screening for breast, 
cervical and colorectal cancer in Europe. We are asking you to use your own knowledge to 
characterise the key elements that make up the overall cancer screening system in your country. We 
realise that, in some countries, screening does not take place within an organised programme and, 
even where there is a programme, some activities may take place outside it; at this stage that is not 
a problem as we want to get a picture of the overall system.  
We have identified a number of sub-systems that, ideally, would be in place to ensure the optimal 
operation of the overall cancer screening system. These sub-systems are: 
1. to generate knowledge that can assist in deciding which conditions should be screened for, 
among which groups (e.g. by age) and how screening should be undertaken, both technically and 
organisationally 
2.     to identify the entire population at risk and to provide their details to those operating the 
system  
3. to ensure the best possible uptake, identifying those who are less likely to undergo 
screening and, where appropriate, to devise interventions to improve their uptake 
4. to ensure the sustainable operation of the screening programme.  
5. to ensure that those who are identified as requiring further investigation are followed up 
adequately 
6. to ensure access to effective treatment for those who need it 
In the following survey we would like you to describe the key elements of each subsystem for your 
country and identify any known barriers to an effective cancer screening system.  Please respond to 
the questions for breast, cervical, and colorectal cancer as a whole and highlight any specific 
differences for each particular cancer type in the final section. 
Which country are you from? 
Choose 
Albania 
Austria 
Belgium 
Bulgaria 
Croatia 
Cyprus 
Czech Republic 
Denmark 
Estonia 
Finland 
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France 
Georgia 
Germany 
Hungary 
Iceland 
Ireland 
Italy 
Latvia 
Lithuania 
Luxembourg 
Malta 
Montenegro 
Netherlands 
Norway 
Poland 
Portugal 
Romania 
Serbia 
Slovenia 
Spain 
Sweden 
Switzerland 
Tunisia 
United Kingdom 
Other 
 
What is your job role? 
National screening organisation 
Policy maker 
Researcher 
Other: 
3 
 
Knowledge generation 
In this section we aim to identify how it is determined which conditions should be 
screened for and how screening should be undertaken, both technically and 
organisationally. 
 
Who is responsible for assessing cancer screening needs, evaluating evidence and system design? 
National health authority / Ministry of Health 
National screening organisation 
Regional/municipal health authority 
Local centres 
Professional body 
Other: 
 
What skills and expertise do they have access to?  
Access to clinical experts 
Access to health system/health policy experts 
Link to universities 
Links to national institutes 
Links to other European collaborators 
Links to other international collaborators 
Other: 
 
What are the barriers to knowledge generation? Please check all that apply and add any further 
barriers.  
Screening guidelines and protocols are not regularly updated 
Complex administrative procedures delay protocol amendment 
Inadequate national governance structure responsible for assessing needs 
Insufficient number of trained professionals with knowledge of screening programmes 
Screening providers do not follow protocols and procedures 
Insufficient monitoring of screening programmes (uptake, acceptability and outcomes) 
Other: 
4 
 
Identification of the eligible population 
In this section we would like to understand how the populations eligible for breast, 
cervical and colorectal cancer screening are identified and informed, including the 
level of participation achieved. 
 
Which register is used to identify those requiring screening? 
Population register 
Health insurance register 
Primary care register 
Other: 
 
Which authority maintains this register? 
National authority 
Regional/municipal authority 
Health insurance fund 
Screening programme 
Other: 
 
How is the register updated with change of address, death and other criteria? 
Updated in real time / weekly 
Updated every 2-3 weeks 
Updated every 1-3 months 
Updated every 4-6 months 
Updated every 6+ months 
Ad hoc updates 
No organisation of regular updates 
Other: 
 
Who is missing from the register? (Examples might include homeless people, migrants etc.) 
Free text 
 
How are eligible patients invited for screening? 
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Letter 
Phone call 
Email 
At visit to primary care physician 
Other: 
 
How are screening appointments arranged? 
Schedule appointment provided - no option for change 
Scheduled appointment provided - option to change 
Choice of several scheduled appointments 
Contact details provided for invitee to ring and book appointment 
Other: 
 
What are the follow-up procedures after screening invitation? 
Reminder letter sent after 0-3 months 
Reminder phone call after 0-3 months 
Reminder letter sent after 4-6 months 
Reminder phone call after 4-6 months 
Reminder letter sent after 6+ months 
Reminder phone call after 6+ months 
Other: 
 
How is attendance at screening monitored? 
All invitees monitored at a national level 
All invitees monitored at a regional/municipal level 
All invitees monitored at a local level 
Ad hoc monitoring 
No monitoring 
Other: 
 
What are the barriers to identification? Please check all that apply and add any further barriers. 
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Population register is not accurate or complete 
Population register is not sufficiently updated with changes of address 
Some eligible patients are not included in the population register 
Screening organisation has insuffiient capacity to invite all those who are eligible 
Eligibility criteria vary according to location 
No follow-up of non-responders after initial screening invitation 
The cost of screening is not covered by health insurance funds 
People who are invited for screening may not have health insurance 
Incomplete consent prevents screening 
Other: 
Maximising uptake (informed participation) 
In this section we aim to understand those who are less likely to undergo screening, 
despite being informed, and how this is monitored. 
 
Who is responsible for monitoring participation? 
National health authority/Ministry of Health 
National screening organisation 
Regional/municipal health authority 
Local centres 
Ad hoc research by various organisations 
No monitoring 
Other: 
 
What population sub-groups do they monitor? 
Ethnicity 
Gender 
Age 
Socioeconomic status 
Religion 
Language 
Other: 
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Do not know 
 
What are the barriers to maximising informed participation? Please check all that apply and add 
any further barriers. 
Appointments for screening make it difficult for people to attend 
Primary care physicians are not sharing information or promoting screening 
Inadequate system for monitoring levels and patterns of screening participation 
Insufficient monitoring quality of screening experiences 
Inadequate responsiveness to problems found in monitoring and feedback 
Opportunistic screening occurs outside of the routine screening programme 
Some people have beliefs and values that lead to non-participation 
Some people experience practical issues that lead to non-participation 
Other: 
Operation of the program 
In this section we aim to understand how the screening programme operates and the 
barriers to the effective management of screening programs. 
 
Who establishes protocols and processes for screening? 
National health authority / Ministry of Health 
National screening organisation 
Professional body 
Regional/municipal health authority 
Local guidelines committees 
Other: 
 
How are protocols and processes established? 
European guidelines for screening are adopted as they are 
Amended from European screening quality guidelines 
Based on a review of the available evidence 
Following an internationally accepted development process such as 'AGREE'? 
Other: 
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How is quality of the screening process monitored? 
Comprehensive quality assurance system, looking at all aspects of screening, in place 
Monitoring of technical quality of the process of screening (e.g. quality of Pap smears) 
Regular monitoring of the experiences of those undergoing screening 
Critical incident reporting 
Regular monitoring of positive/negative results, positive predictive value and/or specificity 
What steps, if any, are taken to remedy problems? 
 
What are the barriers to successful operation of the program? Please check all that apply and add 
any further barriers. 
 
Private ownership of screening facilities hinders optimal screening practices 
Limited capacity of screening programme (insufficient human, physical and financial resources) 
Monitoring and evaluation is inadequate and insufficient 
Significant organisational and logistical problems 
Issues with establishing protocols, processes and legal frameworks 
Inadequate and/or disjointed information technology (IT) systems 
Inadequate organisational/administration support for clinical professionals 
Providers don’t always work to agreed guidelines and protocols 
Outcome data from opportunistic screening is not collected and shared 
Opportunistic testing does not keep the same evidence-based screening policy 
Opportunistic testing causes additional costs for overall healthcare system 
Limited public promotion of the screening programme 
Other: 
Follow-up 
This sections evaluates what is being done to ensure that those who are identified as 
requiring further investigation are followed up adequately.  
 
Who is responsible for ensuring follow-up of those requiring further investigation? 
National health authority/Ministry of Health 
National screening organisation 
Regional/municipal health authority 
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Other: 
 
What measures are taken to ensure the follow-up of screen positive cases? 
Free text 
 
What is done in respect of non-responders? 
Reminder letter 
Phone call 
Contact primary care physician 
Other: 
 
What are the barriers to follow-up? Please check all that apply and add any further barriers. 
Poor laboratory quality results in false negative results and patients not followed up 
No well-defined organising body or system in place for follow-up activities 
Insufficient monitoring and evaluation of non-responders 
Insufficient resources for follow-up activities 
Poor adherence by providers to guidelines on follow-up investigations 
Clinician’s attitudes and established patterns of practice prevent follow-up 
Difficulties sharing data between clinics regionally and nationally 
Poor communication between screening organizations, primary care and patients 
Current system does not address personal beliefs about follow-up (e.g. fatalism) 
Insufficient evaluation of the objective obstacles facing patients requiring follow-up 
Other: 
Treatment 
This section investigates who ensures access to effective treatment for those who 
need it  
 
Who is responsible for ensuring those screened get treatment, if required? 
National health authority/Ministry of Health 
National screening organisation 
Regional/municipal health authority 
10 
 
Local centres 
Individual physicians/healthcare professionals 
The individual 
Other: 
 
Who monitors uptake and outcomes of treatment? 
National health authority/Ministry of Health 
National screening organisation 
Regional/municipal health authority 
Local centres 
Individual physicians/healthcare professionals 
The individual 
Other: 
 
What links, if any, are in place to link screening data to cancer registries? 
Free text 
 
What are the barriers to effective treatment? Please check all that apply and add any further 
barriers. 
Insufficient monitoring is done on those testing screening positive 
Effective treatment is not available to all who require it 
No systematic monitoring or evaluation of treatment outcomes 
Information on the management chain is not tracked systematically 
There are difficulties sharing and accessing data across different regions 
Patients do not undergo treatment because of a variety of personal beliefs 
Patients do not undergo treatment because of a variety of objective obstacles 
Other: 
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Differences between breast, cervical and colorectal cancer screening 
systems 
In this section, we would like to identify any differences in the way the programmes 
are organised for breast, cervical and colorectal cancer and any differences in the 
barriers experienced in your country.  Please refer back to your previous answers. 
 
What, if any, are the main differences between the three cancer screening systems in your 
country?  
Free text 
 
In terms of barriers to effective screening, what, if any, are the differences between the three 
cancer screening systems in your country?  
Free text 


Figure S1: Percentage of countries reporting barriers to knowledge generation (by survival subgroup)  
 
Key to subgroups: 
All Europe: all countries included in study (n=31).  Survival group 1 (n=4): Scandinavia (Finland, Iceland, Norway and Sweden).  In the CONCORD-
3 study report (Allemani et al. 2018), overall these countries had the best cancer survival in Europe.  For breast, cervix and colon cancer, all four 
countries were in the top seven best European countries in terms of in terms of age-standardised five-year net survival (%) in adults 15-99 years 
using 2010-2014 data.  Survival group 2 (n=11): Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland 
and United Kingdom.  In the CONCORD-3 study report (Allemani et al. 2018), these countries all had survival of 60-69% (colon), 85% or higher 
(breast) and 60% or higher (cervix).  Survival group 3 (n=16):  all countries included in this study not in groups 1 or 2.  Ref: Allemani C, et al. 
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with 
one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75. 
 
The BEST tool asked the following multiple choice question for each sub-system: “What are the barriers to knowledge generation/ identification 
(of the eligible population)/maximising uptake (informed participation)/successful operation of a programme/(adequate) follow-up/effective 
treatment (for those that need it)?  Please check all that apply and add any further barriers”  
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Figure S2: Percentage of countries reporting barriers to identifying the eligible population (by survival subgroup) 
 
Key to subgroups: 
All Europe: all countries included in study (n=31).  Survival group 1 (n=4): Scandinavia (Finland, Iceland, Norway and Sweden).  In the CONCORD-
3 study report (Allemani et al. 2018), overall these countries had the best cancer survival in Europe.  For breast, cervix and colon cancer, all four 
countries were in the top seven best European countries in terms of in terms of age-standardised five-year net survival (%) in adults 15-99 years 
using 2010-2014 data.  Survival group 2 (n=11): Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland 
and United Kingdom.  In the CONCORD-3 study report (Allemani et al. 2018), these countries all had survival of 60-69% (colon), 85% or higher 
(breast) and 60% or higher (cervix).  Survival group 3 (n=16):  all countries included in this study not in groups 1 or 2.  Ref: Allemani C, et al. 
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with 
one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75. 
 
The BEST tool asked the following multiple choice question for each sub-system: “What are the barriers to knowledge generation/ identification 
(of the eligible population)/maximising uptake (informed participation)/successful operation of a programme/(adequate) follow-up/effective 
treatment (for those that need it)?  Please check all that apply and add any further barriers”  
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Figure S3: Percentage of countries reporting barriers to maximising uptake (informed participation) (by survival 
subgroup) 
 
Key to subgroups: 
All Europe: all countries included in study (n=31).  Survival group 1 (n=4): Scandinavia (Finland, Iceland, Norway and Sweden).  In the CONCORD-
3 study report (Allemani et al. 2018), overall these countries had the best cancer survival in Europe.  For breast, cervix and colon cancer, all four 
countries were in the top seven best European countries in terms of in terms of age-standardised five-year net survival (%) in adults 15-99 years 
using 2010-2014 data.  Survival group 2 (n=11): Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland 
and United Kingdom.  In the CONCORD-3 study report (Allemani et al. 2018), these countries all had survival of 60-69% (colon), 85% or higher 
(breast) and 60% or higher (cervix).  Survival group 3 (n=16):  all countries included in this study not in groups 1 or 2.  Ref: Allemani C, et al. 
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with 
one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75. 
 
The BEST tool asked the following multiple choice question for each sub-system: “What are the barriers to knowledge generation/ identification 
(of the eligible population)/maximising uptake (informed participation)/successful operation of a programme/(adequate) follow-up/effective 
treatment (for those that need it)?  Please check all that apply and add any further barriers”  
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Figure S4: Percentage of countries reporting barriers to successful operation of a programme (by survival subgroup) 
 
Key to subgroups: 
All Europe: all countries included in study (n=31).  Survival group 1 (n=4): Scandinavia (Finland, Iceland, Norway and Sweden).  In the CONCORD-
3 study report (Allemani et al. 2018), overall these countries had the best cancer survival in Europe.  For breast, cervix and colon cancer, all four 
countries were in the top seven best European countries in terms of in terms of age-standardised five-year net survival (%) in adults 15-99 years 
using 2010-2014 data.  Survival group 2 (n=11): Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland 
and United Kingdom.  In the CONCORD-3 study report (Allemani et al. 2018), these countries all had survival of 60-69% (colon), 85% or higher 
(breast) and 60% or higher (cervix).  Survival group 3 (n=16):  all countries included in this study not in groups 1 or 2.  Ref: Allemani C, et al. 
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with 
one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75. 
 
The BEST tool asked the following multiple choice question for each sub-system: “What are the barriers to knowledge generation/ identification 
(of the eligible population)/maximising uptake (informed participation)/successful operation of a programme/(adequate) follow-up/effective 
treatment (for those that need it)?  Please check all that apply and add any further barriers”  
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Figure S5: Percentage of countries reporting barriers to effective follow-up (by survival subgroup) 
 
Key to subgroups: 
All Europe: all countries included in study (n=31).  Survival group 1 (n=4): Scandinavia (Finland, Iceland, Norway and Sweden).  In the CONCORD-
3 study report (Allemani et al. 2018), overall these countries had the best cancer survival in Europe.  For breast, cervix and colon cancer, all four 
countries were in the top seven best European countries in terms of in terms of age-standardised five-year net survival (%) in adults 15-99 years 
using 2010-2014 data.  Survival group 2 (n=11): Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland 
and United Kingdom.  In the CONCORD-3 study report (Allemani et al. 2018), these countries all had survival of 60-69% (colon), 85% or higher 
(breast) and 60% or higher (cervix).  Survival group 3 (n=16):  all countries included in this study not in groups 1 or 2.  Ref: Allemani C, et al. 
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with 
one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75. 
 
The BEST tool asked the following multiple choice question for each sub-system: “What are the barriers to knowledge generation/ identification 
(of the eligible population)/maximising uptake (informed participation)/successful operation of a programme/(adequate) follow-up/effective 
treatment (for those that need it)?  Please check all that apply and add any further barriers”  
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Figure S6: Percentage of countries reporting barriers to effective treatment (by survival subgroup) 
 
Key to subgroups: 
All Europe: all countries included in study (n=31).  Survival group 1 (n=4): Scandinavia (Finland, Iceland, Norway and Sweden).  In the CONCORD-
3 study report (Allemani et al. 2018), overall these countries had the best cancer survival in Europe.  For breast, cervix and colon cancer, all four 
countries were in the top seven best European countries in terms of in terms of age-standardised five-year net survival (%) in adults 15-99 years 
using 2010-2014 data.  Survival group 2 (n=11): Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland 
and United Kingdom.  In the CONCORD-3 study report (Allemani et al. 2018), these countries all had survival of 60-69% (colon), 85% or higher 
(breast) and 60% or higher (cervix).  Survival group 3 (n=16):  all countries included in this study not in groups 1 or 2.  Ref: Allemani C, et al. 
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with 
one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75. 
 
The BEST tool asked the following multiple choice question for each sub-system: “What are the barriers to knowledge generation/ identification 
(of the eligible population)/maximising uptake (informed participation)/successful operation of a programme/(adequate) follow-up/effective 
treatment (for those that need it)?  Please check all that apply and add any further barriers”  
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Table 1: Percentage of countries reporting barriers from each sub-system* in BEST tool (all and by European region) 
 Barriers from BEST sub-system All North East South West 
Number of countries in region 31 7 10 5 9 
K
no
w
le
dg
e 
Complex administrative procedures delay protocol amendment 65% 43% 60% 40% 100% 
Insufficient number of trained professionals with knowledge of screening 
programmes 
65% 71% 50% 80% 67% 
Insufficient monitoring of screening programmes (uptake, acceptability and 
outcomes) 
58% 57% 50% 60% 67% 
Inadequate national governance structure responsible for assessing needs 55% 71% 40% 80% 44% 
Screening guidelines and protocols are not regularly updated 48% 57% 50% 20% 56% 
Screening providers do not follow protocols and procedures 39% 43% 50% 40% 22% 
Id
en
tif
ic
at
io
n 
Population register is not sufficiently updated with changes of address 48% 29% 60% 80% 33% 
No follow-up of non-responders after initial screening invitation 45% 29% 50% 40% 56% 
Some eligible patients are not included in the population register 45% 14% 50% 40% 67% 
Population register is not accurate or complete 39% 0% 50% 80% 33% 
Screening organisation has insufficient capacity to invite all those who are eligible 32% 14% 40% 40% 33% 
Pa
rt
ic
ip
at
io
n 
Opportunistic screening occurs outside of the routine screening programme 87% 86% 80% 100% 89% 
Some people have beliefs and values that lead to non-participation 77% 71% 60% 80% 100% 
Primary care physicians are not sharing information or promoting screening 61% 57% 60% 60% 67% 
Some people experience practical issues that lead to non-participation 58% 57% 60% 60% 56% 
Insufficient monitoring quality of screening experiences 52% 57% 60% 60% 33% 
Inadequate system for monitoring levels and patterns of screening participation 45% 57% 60% 40% 22% 
Inadequate responsiveness to problems found in monitoring and feedback 39% 43% 50% 60% 11% 
Appointments for screening make it difficult for people to attend 23% 29% 20% 0% 33% 
O
pe
ra
tio
n 
Outcome data from opportunistic screening is not collected and shared 71% 43% 80% 80% 78% 
Inadequate and/or disjointed information technology (IT) systems 71% 86% 80% 60% 56% 
Limited capacity of screening programme (insufficient human, physical and 
financial resources) 
68% 57% 100% 60% 44% 
Opportunistic testing does not keep the same evidence-based screening policy 68% 43% 90% 60% 67% 
Opportunistic testing causes additional costs for overall healthcare system 65% 57% 60% 80% 67% 
Issues with establishing protocols, processes and legal frameworks 58% 43% 70% 60% 56% 
Significant organisational and logistical problems 48% 29% 70% 60% 33% 
Providers don’t always work to agreed guidelines and protocols 48% 29% 50% 40% 67% 
Monitoring and evaluation is inadequate and insufficient 45% 29% 50% 60% 44% 
Limited public promotion of the screening programme 45% 29% 70% 40% 33% 
Inadequate organisational/administration support for clinical professionals 39% 14% 70% 40% 22% 
Private ownership of screening facilities hinders optimal screening practices 26% 14% 30% 20% 33% 
Fo
llo
w
-u
p 
Insufficient monitoring and evaluation of non-responders 58% 29% 90% 60% 44% 
No well-defined organising body or system in place for follow-up activities 48% 29% 60% 40% 56% 
Difficulties sharing data between clinics regionally and nationally 42% 43% 50% 20% 44% 
Poor adherence by providers to guidelines on follow-up investigations 35% 29% 50% 0% 44% 
Poor communication between screening organizations, primary care and patients 35% 29% 60% 0% 33% 
Clinician’s attitudes and established patterns of practice prevent follow-up 35% 0% 60% 40% 33% 
Current system does not address personal beliefs about follow-up (e.g. fatalism) 29% 29% 40% 0% 33% 
Insufficient evaluation of the objective obstacles facing patients requiring follow-up 29% 14% 40% 0% 44% 
Insufficient resources for follow-up activities 29% 14% 50% 40% 11% 
Tr
ea
tm
en
t 
No systematic monitoring or evaluation of treatment outcomes 58% 43% 70% 40% 67% 
Information on the management chain is not tracked systematically 55% 14% 90% 40% 56% 
There are difficulties sharing and accessing data across different regions 48% 43% 50% 20% 67% 
Patients do not undergo treatment because of a variety of personal beliefs 42% 14% 50% 40% 56% 
Insufficient monitoring is done on those testing screening positive 32% 29% 40% 20% 33% 
 
Key to subgroups: All Europe: all countries included in study (n=31).  North (n=7): Denmark, Estonia, Finland, Iceland, Latvia, 
Norway and Sweden.  East (n=10): Albania, Croatia, Czech Republic, Georgia, Hungary, Montenegro, Poland, Romania, Serbia 
and Slovenia.  South (n=5): Cyprus, Italy, Malta, Portugal and Spain.  West (n=9): Austria, Belgium, France, Germany, Ireland, 
Luxembourg, Netherlands, Switzerland and United Kingdom.   
 
Notes: * The Barrier to Effective Screening Tool (BEST) asked the following multiple choice question for each sub-system:  
“What are the barriers to [sub-system]?  Please check all that apply and add any further barriers”.  The six sub-systems are as 
follows:  knowledge generation, identification (of the eligible population), maximising uptake (informed participation), successful 
operation of a programme, adequate follow-up, and effective treatment (for those who need it).  Only barriers reported by over 20% 
of all countries reported above. 
 
Table 2: Number (percentage) of all respondents (and countries) reporting barriers from each sub-system* in BEST tool  
 
Barrier from BEST sub-system Number of all 
respondents 
% of all 
respondents 
Number of 
countries  
Number of respondents / countries 67 67 31 
K
no
w
le
dg
e 
Complex administrative procedures delay protocol amendment 32 48% 20 
Insufficient monitoring of screening programmes (uptake, acceptability and 
outcomes) 
26 39% 18 
Insufficient number of trained professionals with knowledge of screening 
programmes 
25 37% 20 
Inadequate national governance structure responsible for assessing needs 25 37% 17 
Screening guidelines and protocols are not regularly updated 20 30% 15 
Screening providers do not follow protocols and procedures 20 30% 12 
Id
en
tif
ic
at
io
n 
Population register is not sufficiently updated with changes of address 26 39% 15 
Some eligible patients are not included in the population register 21 31% 14 
No follow-up of non-responders after initial screening invitation 17 25% 14 
Population register is not accurate or complete 16 24% 12 
Screening organisation has insufficient capacity to invite all those who are 
eligible 
12 18% 10 
Pa
rt
ic
ip
at
io
n 
Some people have beliefs and values that lead to non-participation 47 70% 24 
Opportunistic screening occurs outside of the routine screening programme 43 64% 27 
Some people experience practical issues that lead to non-participation 33 49% 18 
Primary care physicians are not sharing information or promoting screening 32 48% 19 
Insufficient monitoring quality of screening experiences 21 31% 16 
Inadequate system for monitoring levels and patterns of screening 
participation 
19 28% 14 
Inadequate responsiveness to problems found in monitoring and feedback 14 21% 12 
O
pe
ra
tio
n 
Outcome data from opportunistic screening is not collected and shared 36 54% 22 
Limited capacity of screening programme (insufficient human, physical and 
financial resource) 
32 48% 21 
Inadequate and/or disjointed information technology (IT) systems 31 46% 22 
Opportunistic testing does not keep the same evidence-based screening 
policy 
31 46% 21 
Opportunistic testing causes additional costs for overall healthcare system 29 43% 20 
Providers don’t always work to agreed guidelines and protocols 28 42% 15 
Significant organisational and logistical problems 26 39% 15 
Issues with establishing protocols, processes and legal frameworks 22 33% 18 
Limited public promotion of the screening programme 21 31% 14 
Monitoring and evaluation is inadequate and insufficient 20 30% 14 
Inadequate organisational/administration support for clinical professionals 15 22% 12 
Private ownership of screening facilities hinders optimal screening practices 11 16% 8 
Fo
llo
w
-u
p 
Insufficient monitoring and evaluation of non-responders 30 45% 18 
No well-defined organising body or system in place for follow-up activities 22 33% 15 
Difficulties sharing data between clinics regionally and nationally 20 30% 13 
Insufficient resources for follow-up activities 16 24% 9 
Poor communication between screening organizations, primary care and 
patients 
15 22% 11 
Poor adherence by providers to guidelines on follow-up investigations 15 22% 11 
Clinician’s attitudes and established patterns of practice prevent follow-up 13 19% 11 
Insufficient evaluation of the objective obstacles facing patients requiring 
follow-up 
12 18% 9 
Tr
ea
tm
en
t 
No systematic monitoring or evaluation of treatment outcomes 30 45% 18 
Information on the management chain is not tracked systematically 23 34% 17 
Patients do not undergo treatment because of a variety of personal beliefs 22 33% 13 
There are difficulties sharing and accessing data across different regions 20 30% 15 
Insufficient monitoring is done on those testing screening positive 12 18% 10 
 
Key: Number of respondents selecting no barriers in each sub-system (n=67) – knowledge (6), identification (10), uptake (1), 
operation (5), follow-up (10), treatment (10).  Number of respondents selecting ‘other’ barriers in each sub-system (reported in 
section above, n=67) – knowledge (13), identification (18), uptake (13), operation (9), follow-up (14), treatment (10).   
 * The Barrier to Effective Screening Tool (BEST) asked the following multiple choice question for each sub-system:  
“What are the barriers to [sub-system]?  Please check all that apply and add any further barriers”.  The six sub-systems are as 
follows:  knowledge generation, identification (of the eligible population), maximising uptake (informed participation), successful 
operation of a programme, adequate follow-up, and effective treatment (for those who need it).  Only barriers reported by over 10% 
of all countries reported above. 
 
 
 
